, , , , , , , , ,

“Rising Interest in Shingles Vaccine: A Personal Quest to Combat Dementia”

Sri Lanka Digital Media Network

Submit Your Press Release

Get your company news, announcements, launches, appointments and events in front of a wider audience.

NewsDive Financial Chronicle Ceylon Independent Daily FC
Submit Your Press Release →
Publish Across Our Network

Last year, 50-year-old Jenny, a marketing and branding expert from Cambridge, sought the shingles vaccine with a different concern in mind. Having lost three of her four grandparents to dementia, she is eager to prevent a similar fate for herself and sees the shingles vaccine as a potential safeguard.

Jenny’s concerns are echoed by many others. Pharmacies across the UK have noted an increase in requests for the shingles vaccine, with a portion of this surge stemming from heightened anxiety about dementia rather than shingles itself. While some individuals qualify for the vaccine at no cost through the NHS, most under the age of 65 are required to pay approximately £450 for the complete two-dose series.

This uptick in interest follows a series of studies suggesting a possible link between shingles vaccination and reduced dementia risk, although these findings are not definitive. Depending on the methodology, research indicates that vaccination may lower the risk of dementia by up to 20%, particularly in women. The implications of such a vaccine could be significant, especially for a condition that currently lacks a cure. John Todd, a professor of precision medicine at the University of Oxford, remarked, “Imagine a vaccine that became a medicine for dementia. Wow. Wouldn’t that be amazing?”

Recent statistics from Boots illustrate that appointments for shingles vaccinations have more than doubled in the past year, following a 30% increase the year prior. A similar pattern has emerged at Superdrug, where bookings have surged by 41% compared to the previous year.

While many individuals seek the vaccine to prevent shingles, a painful rash resulting from the reactivation of the dormant chickenpox virus, numerous people have expressed that their desire to avert dementia is a significant motivator for their decision. Jenny shared, “I want to feel as if I’ve done everything I can to try to head it off, in terms of risk factors and preventive measures that are available to me now. If there’s a potential for this to give me more time without the onset of dementia in 20 years’ time, then God, I’ll take it.”

Currently, nearly 60 million people worldwide are living with dementia, a figure that is expected to rise due to population growth and aging. By 2040, more than 100 million individuals are anticipated to be affected, with projections indicating that 1.7 million people in England and Wales could have dementia by that year, leading to an annual economic burden of £90 billion.

The most prevalent form of dementia, Alzheimer’s disease, is characterized by the abnormal accumulation of proteins in the brain. Amyloid plaques form between neurons, while tau tangles develop inside nerve cells. Although new treatments can help remove amyloid plaques and slow the disease’s progression, their effects on patients have been limited, and side effects can be severe.

Research into the shingles vaccine has gained momentum due to concerns that the varicella zoster virus (VZV), responsible for chickenpox and shingles, could play a role in the onset of dementia. After a chickenpox infection, some of the virus remains in the body, lying dormant in nerve cells. As the immune system weakens with age or due to medications or stress, the virus can reactivate and cause shingles. In the brain, the virus may provoke inflammation, stress on nerve cells, and the accumulation of amyloid and tau proteins.

In a significant study published in Nature last year, researchers from Stanford University examined a natural experiment in Wales during a shingles vaccination initiative. The Zostavax vaccine, which contains a weakened form of the varicella zoster virus, was made available starting September 1, 2013. However, individuals aged 80 or older on that date were ineligible to receive the vaccine, as its efficacy decreases with age.

This age restriction allowed researchers to compare dementia rates between two groups: those eligible for the vaccine and those who were not. The analysis revealed an 8.5% reduction in dementia rates among the vaccinated group over the span of seven years, particularly in women, though the results for men did not reflect the same trend. The researchers estimated that the vaccine lowered dementia risk by nearly 20%, with similar findings reported in Australia and Ontario, Canada.

According to Pascal Geldsetzer, an epidemiologist involved in the Stanford studies, “We have a really compelling body of data from these studies. We’re much more confident that what we’re looking at is cause and effect rather than just correlation.”

In 2024, further evidence emerged from the University of Oxford, where John Todd collaborated with psychiatrists Maxime Taquet and Paul Harrison to investigate Shingrix, a newer and more effective shingles vaccine that has largely replaced Zostavax. Unlike Zostavax, Shingrix is not a live-attenuated vaccine; it includes viral proteins and an adjuvant designed to enhance the immune response. This adjuvant consists of tiny lipid-based particles containing various compounds that target different aspects of the immune system.

The Oxford researchers analyzed health records of over 200,000 individuals in the US who received the shingles vaccine, with half receiving Shingrix and the other half Zostavax. Over the following six years, dementia cases were found to be 17% lower among those who received Shingrix compared to those who received Zostavax, translating to an additional 164 days lived without the condition. Women experienced a 22% lower risk, while men had a 13% reduction, likely reflecting the fact that women generally have a higher risk of dementia due to longer life expectancy.


AI Search


NewsDive – News Search

NewsDive

Dive deep into the news that matter

🌍 Detecting your location…

Select a Newspaper

Breaking News Latest Business Economy Political Sports Entertainment US-Iran War International

Search Results

Top Categories

Latest News


Sri Lanka


Australia


India


United Kingdom


USA


Sports